2024 年第 1 期 第 19 卷

补肺活血胶囊联合化疗治疗晚期非小细胞肺癌患者的效果及安全性分析

Analysis of efficacy and safety of Bufei Huoxue capsules assisted with chemotherapy in patients with advanced non-small cell lung cancer

作者：卢航超1 楼加伟2

英文作者：Lu Hangchao1 Lou Jiawei2

单位：1中国人民武装警察部队浙江省总队医院内一科，杭州310051；2浙江萧山医院肿瘤内科，杭州311202

英文单位：1The First Department of Internal Medicine Zhejiang Provincial General Hospital Chinese People′s Armed Police Force Hangzhou 310051 China; 2Department of Oncology Xiaoshan Hospital Zhejiang Province Hangzhou 311202 China

关键词：非小细胞肺癌；补肺活血胶囊；化疗；疗效；安全性

英文关键词：Non-smallcelllungcancer;BufeiHuoxuecapsules;Chemotherapy;Efficacy;Safety

• 摘要：

• 目的  分析补肺活血胶囊联合化疗治疗晚期非小细胞肺癌（NSCLC）患者的效果及安全性。方法  选取2020年4月至2023年1月浙江萧山医院收治的126例晚期NSCLC患者，按随机数字表法分为对照组与观察组，各63例。对照组采用紫杉醇联合顺铂化疗方案治疗；观察组在对照组基础上予补肺活血胶囊治疗。比较2组临床疗效、肺功能指标、肿瘤标志物水平及不良反应发生情况。结果  观察组总有效率高于对照组［92.1%（58/63）比77.8%（49/63）］（P=0.037）。治疗后，2组一氧化碳弥散量占预计值百分比、肺活量均高于治疗前，且观察组均高于对照组（均P<0.05）。治疗12周后，2组癌胚抗原、糖类抗原125及细胞角蛋白19片段水平均低于治疗前，且观察组均低于对照组（均P<0.05）。观察组不良反应发生率均低于对照组（均P＜0.05）。结论  与单独采用化疗方案相比，采用补肺活血胶囊联合化疗治疗晚期NSCLC患者，更有助于提高临床效果，改善肺功能，降低肿瘤标志物水平，减少不良反应的发生。

• Objective  To analyse the efficacy and safety of Bufei Huoxue capsules assisted with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Methods  Totally 126 patients with advanced NSCLC admitted to Xiaoshan Hospital, Zhejiang Province from April 2020 to January 2023 were selected. They were divided into control group and observation group according to the random number table method, with 63 cases in each group. The control group was treated with paclitaxel combined with cisplatin chemotherapy, and the observation group was treated with Bufei Huoxue capsules on the basis of the control group. The clinical efficacy, lung function indexes, tumor markers and adverse reactions were compared between the two groups. Results  The effective rate of observation group was higher than that of control group ［92.1%（58/63） vs 77.8%（49/63）］（P=0.037）. After therapy, the diffusion capacity for carbon monoxide as a percentage of predicted value and vital capacity in the two groups were higher than those before therapy, and the observation group was higher than the control group (all P<0.05). Twelve weeks after therapy, the levels of carcinoembryonic antigen, cancer antigen 125 and cytokeratin 19 fragment in two groups were lower than those before therapy, and the observation group was lower than the control group (all P<0.05). The rates of adverse reaction of the observation group were lower than those of the control group (all P<0.05). Conclusions  Compared with chemotherapy alone, Bufei Huoxue capsules combined with chemotherapy in the treatment of patients with advanced NSCLC were more conducive to improving the clinical efficacy and lung function, reducing the levels of tumor markers and the occurrence of adverse reactions.